Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis <scp>C</scp> Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy

Moreira, Sebastian; Morcos, Peter N.; Navarro, Mercidita T.; Bech, Nuria; Smith, Patrick F.; Brennan, Barbara J.

doi:10.1002/phar.1341

Pharmacotherapy

2013

DOI: 10.1002/phar.1341

|View full text |Cite

Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy

Sebastian Moreira

Peter N. Morcos

Mercidita T. Navarro³

et al.

Abstract: Coadministration of DNVr with MMT resulted in no significant pharmacokinetic interactions or signs of methadone withdrawal. No dosage adjustment is needed for MMT when coadministered with DNVr.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2023

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Danoprevir: First Global Approval

Markham

Keam

2018

Drugs

View full text Add to dashboard Cite

Ascletis has developed danoprevir (Ganovo), an orally-administered hepatitis C virus NS3 protease inhibitor, as a treatment for hepatitis C. Based on positive results in phase II and phase III trials in patients with hepatitis C, danoprevir, in combination with ritonavir, peginterferon alfa and ribavirin was recently approved for marketing in China for the treatment of treatment-naive patients with non-cirrhotic genotype 1b chronic hepatitis C. This article summarizes the milestones in the development of danoprevir leading to this first approval.

show abstract

Danoprevir: First Global Approval

Markham

Keam

2018

Drugs

View full text Add to dashboard Cite

show abstract

Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review

Volpe

Sahajwalla

et al. 2018

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update

Zhao

Yuan

et al. 2023

CDM

View full text Add to dashboard Cite

Antiretroviral therapy is the recognized treatment for human immunodeficiency virus (HIV) infection involving several antiviral agents. Even though highly active antiretroviral therapy has been proven to be very effective in suppressing HIV replication, the antiretroviral drugs, belonging to different pharmacological classes, present quite complex pharmacokinetic properties such as extensive drug metabolism and transport by membrane-associated drug carriers. Moreover, due to uncomplications or complications in HIV-infected populations, an antiretroviral-based multiple-drug coadministration therapy strategy is usually applied for treatment effect, thus raising the possibility of drugdrug interactions between antiretroviral drugs and common drugs such as opioids, stains, and hormonal contraceptives. Herein, thirteen classical antiretroviral drugs approved by US Food and Drug Administration were summarized. Besides, relative drug metabolism enzymes and transporters known to interact with those antiretroviral drugs were detailed and described. Furthermore, one after the summarized antiretroviral drugs, the drug-drug interactions between two antiretroviral drugs or antiretroviral drug - conventional medical drugs of the past decade were discussed and summarized. This review is intended to deepen the pharmacological understanding of antiretroviral drugs and promote more secure clinical applications for antiretroviral drugs to treat HIV.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Effect of Ritonavir‐Boosted Danoprevir, a Potent Hepatitis C Virus Protease Inhibitor, on the Pharmacokinetics of Methadone in Healthy Subjects Undergoing Methadone Maintenance Therapy

Abstract: Coadministration of DNVr with MMT resulted in no significant pharmacokinetic interactions or signs of methadone withdrawal. No dosage adjustment is needed for MMT when coadministered with DNVr.

Cited by 3 publications

References 43 publications

Danoprevir: First Global Approval

Danoprevir: First Global Approval

Methadone Metabolism and Drug-Drug Interactions: In Vitro and In Vivo Literature Review

Pharmacokinetic Drug-Drug Interactions Involving Antiretroviral Agents: An Update

Contact Info

Product

Resources

About